Triple Negative Breast Cancer
Patients with mTNBC have a poor prognosis, with a median overall survival of 13.3 months despite treatment, and up to a 25% recurrence rate after surgical intervention. Although immunotherapy has recently shown promising clinical results as a first-line treatment, single-agent chemotherapy remains the standard for previously treated mTNBC.
However, patients with mTNBC usually relapse shortly after treatment with chemotherapy, likely as a result of acquired resistance. The low response rates, short progression-free survival and considerable toxicity profiles associated with chemotherapies suggests an urgent need for new treatment strategies for mTNBC.
